Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
Veronika Mančíková, Michal Šmída
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease.
Topics & Concepts
Chronic lymphocytic leukemiaChimeric antigen receptorMedicineCAR T-cell therapyLeukemiaImmunologyDiseaseAntigenCell therapyCellCancer researchImmunotherapyOncologyInternal medicineImmune systemBiologyGeneticsCAR-T cell therapy research